Clinical Trials Browser

Phase 2 × Carcinoma, Non-Small-Cell Lung × Dasatinib × Clear all

NCT01514864 2023-12-19

Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Phase 2 Terminated

19 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT04284202 2020-02-25

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00459342 2019-03-05

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2 Completed

35 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00787267 2016-06-30

TOP0801

Phase 2 Terminated

37 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00570401 2016-01-22

Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

Phase 2 Completed

22 enrolled 6 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00564876 2015-02-23

TOP0706

Phase 2 Terminated

2 enrolled 4 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung